Earnings Call

Research Frontiers' Q2 call is more than numbers; it’s a window into the multi-billion dollar smart glass market and a unique IP-driven business model.

As DarioHealth prepares its Q2 results, investors are watching closely. Can its disciplined cost-cutting and AI-powered platform deliver on the promise of profitability?

Heritage Global Inc. is strategically winding down its specialty finance unit, bracing for a major Q2 write-down amid rising non-performing loans.

As specialty insurer Trisura Group readies its Q2 results, investors are watching to see if its growth can navigate market shifts and justify high expectations.

Roblox's Q2 earnings reveal a complex picture: impressive revenue growth overshadowed by decelerating bookings and a strategic pivot toward long-term gains.

As CapsoVision preps its Q2 report, investors look past the numbers to its AI-driven pipeline, a key test of its strategy to reshape GI diagnostics.

As Vuzix prepares its Q2 2026 earnings call, investors will look past the numbers to a bigger question: can its pivot to an OEM model unlock its AR potential?

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

As Dollar General preps its Q2 earnings, all eyes are on what its results will reveal about inflation, consumer shifts, and the health of the U.S. economy.

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

Anterix's upcoming earnings report isn't just for investors. It's a crucial look at the hidden infrastructure powering our AI, EV, and climate-resilient future.

After a major Q4 earnings miss, all eyes are on Universal Corp's upcoming call. Can it justify its dividend and prove its strategic pivot is working?

As LEEF Brands preps its Q2 results, its soaring margins clash with a "going concern" warning, making it a crucial case study for survival in the state's cannabis market.

As Hamilton Beach sets its Q2 earnings call, the focus is less on kitchen gadgets and more on its strategic pivot into healthcare and commercial markets.

As Hyperion DeFi (HYPD) preps its Q2 report, the market awaits a first look into the viability of a publicly-traded company built on a DeFi protocol.

As RenovoRx preps its Q2 update, it's proving its mettle on two fronts: impressive sales of its RenovoCath device and a critical milestone in its pancreatic cancer trial.

With a history of beating expectations and a new acquisition in tow, all eyes are on Calian's Q3 results to see if its mission-critical strategy can sustain momentum.

While its Learning division thrives on acquisitions and AI, Finnish media giant Sanoma navigates advertising slumps, betting its future on an ed-tech transformation.

With its wind tower business in the rearview, Broadwind's upcoming earnings call is the first look at its new life as a precision manufacturing specialist.